Phase I
Asceneuron SA announced today it has commenced a new clinical trial of its lead asset, ASN120290.
Overall response rate at 28 days of 60%, complete response rate of 50%
Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.
Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment
Potential new immune-oncology therapy uses antibody drug conjugate (ADC) that targets regulatory T cells (Tregs)
Botanix has treated the first patient in its BTX 1308 psoriasis Phase 1b patient study
Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.
Phase 1 data show favourable safety profile
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
PRESS RELEASES